Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Down 22.1% in July

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totalling 11,300 shares, a decrease of 22.1% from the June 30th total of 14,500 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily volume of 16,600 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Lisata Therapeutics in a research note on Friday, July 19th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lisata Therapeutics stock. BML Capital Management LLC increased its holdings in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 269,839 shares of the company’s stock after purchasing an additional 26,000 shares during the quarter. Lisata Therapeutics makes up about 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 24th biggest holding. BML Capital Management LLC owned 3.31% of Lisata Therapeutics worth $737,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Stock Performance

NASDAQ:LSTA traded down $0.05 during trading hours on Friday, hitting $3.39. The stock had a trading volume of 3,817 shares, compared to its average volume of 15,001. Lisata Therapeutics has a one year low of $1.95 and a one year high of $3.83. The company has a market cap of $28.13 million, a price-to-earnings ratio of -1.38 and a beta of 1.24. The business’s 50 day moving average is $3.35 and its 200-day moving average is $3.07.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08. On average, sell-side analysts anticipate that Lisata Therapeutics will post -3.08 EPS for the current fiscal year.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.